Edition:
India

People: aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

0.47USD
14 Dec 2018
Change (% chg)

$-0.01 (-2.45%)
Prev Close
$0.49
Open
$0.46
Day's High
$0.48
Day's Low
$0.45
Volume
52,236
Avg. Vol
73,677
52-wk High
$4.20
52-wk Low
$0.45

Hatfield, Jeffrey 

Mr. Jeffrey S. Hatfield is Director of the Company. Mr. Hatfield most recently served as President, Chief Executive Officer and a member of the Board of Directors of Vitae Pharmaceuticals (“Vitae”) from 2004 to 2016. Mr. Hatfield took Vitae public in 2014, and in October 2016, Vitae was acquired by Allergan plc. Prior to joining Vitae, Mr. Hatfield worked at Bristol-Myers Squibb in a variety of executive positions, including: Senior Vice President of BMS’s Immunology and Virology Divisions, where he was responsible for all aspects of the $1 billion business; President and General Manager, Canada; and Vice President, U.S. Managed Health Care. He previously served as a Board member of Ambit Biosciences before its acquisition by Daiichi-Sankyo in 2015, and as a member of the Board of Directors of the Biotechnology Industry Organization (BIO), serving on the Executive Company Section. Mr. Hatfield currently serves as a Board member of InVivo Therapeutics, a biotechnology company, and as a member of the Advisory Committees for: Purdue University’s College of Pharmacy, where he is a Distinguished Alumni and is on faculty; Drexel University’s LeBow College of Business; and the Chapman-KGI School of BioPharmacy. Mr. Hatfield holds an M.B.A. from The Wharton School, University of Pennsylvania and a bachelor’s degree in Pharmacy from Purdue University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --